Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday. Shares of Moderna ...
CoV-2, has been discovered in China and is “strikingly similar to the pandemic virus” and feared to be powerful ...
While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...
Researchers at Yale University in a small, yet to be published study found that Covid vaccines were linked to a rare ...
The postponed ACIP meeting comes barely a week after Robert F. Kennedy, Jr. was confirmed as Secretary of Health and Human ...
The Montana House of Representatives on Wednesday voted overwhelmingly against House Bill 371, a measure that would have banned mRNA vaccines — used primarily in COVID-19 vaccines and booster shots — ...
HOSPITALS in England have been hit by a storm of norovirus infections, with cases reaching a record high. As well as bouts of ...
The “Make America Healthy Again” commission is reviewing certain vaccines as some states push to restrict the use of COVID-19 ...
In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to ...
Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...